Cytologic analysis of pancreatic juice increases specificity of detection of malignant IPMN—a systematic review
Abstract
Background & aims Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas can progress to cancer. Biomarkers have been identified that were reported to increase the accuracy of identification of malignant lesions; we performed a systematic review of the accuracy of these markers. Methods We performed a systematic review of published studies on biomarkers of malignant IPMNs by searching MEDLINE and Web of Science databases from January 2005 through December 2017. Our methods were developed based on the Meta-analysis Of Observational Studies in Epidemiology guidelines. Pooled sensitivity, specificity, receiver operating characteristic curves, and their respective areas under the curve (AUC) were calculated from groups of markers (cell-, protein-, or DNA-based) measured in samples collected before and after surgery. A hypothetical test model was developed to determine how to meaningfully amend the revised Fukuoka guidelines, focusing on increasing test specificity for patients with IPMNs that have worrisome features. Results We collected data from 193 published studies, comprising 12,297 patients, that analyzed 7 preoperative and 21 postoperative markers of IPMNs. The 3 biomarkers that identified malignant IPMNs with the largest AUC values were pancreatic juice cytology (AUC, 0.84; sensitivity, 0.54; specificity, 0.91), serum protein carbohydrate antigen 19-9 (AUC, 0.81; sensitivity, 0.45; specificity, 0.90), and cyst fluid cytology (AUC, 0.82; sensitivity, 0.57; specif…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The citation lists haven’t been fetched yet
References 119 · Cited by 36
- Authors
- Tanaka, M., Heckler, M., Liu, B., Heger, U., Hackert, T., & Michalski, C. W.
- Affiliations
- Heidelberg University (DE)
- Corresponding author
- Hackert, Thilo
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 17
- Issue
- 11
- Pages
- 2199-2211.e21
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2908606368
- Cited by
- 36
- References
- 119
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 9 · 2019: 3
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ernst Freiberger Foundation
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- intraductal papillary mucinous neoplasm, pancreatic juice cytology, pancreatic cancer detection, biomarkers, CA19-9, cyst fluid cytology, MUC1, MUC2, immunohistochemistry, diagnostic specificity, preoperative diagnosis
- MeSH terms
- Pancreatic Intraductal Neoplasms, Humans, Pancreas, Pancreatic Juice, Pancreatic Neoplasms, Biomarkers, Tumor, Reproducibility of Results, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review